SBEβCD-Bicarbonate Meloxicam Formulation for Faster Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID formulation, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to solubilize meloxicam. The cyclodextrin molecules form inclusion complexes with meloxicam, where the hydrophobic interior of the cyclodextrin cavity accommodates the meloxicam molecule while the hydrophilic exterior interacts with aqueous environments. This mediator approach transforms the poorly soluble meloxicam into a water-soluble complex, thereby improving bioavailability and accelerating the onset of pain relief without altering the fundamental pharmacological properties of meloxicam
2Reliability
If cyclodextrins are used to increase solubility of meloxicam, then bioavailability is improved, but the formulation complexity increases
Solution Approach 1:
The patent employs pre-formed cyclodextrin inclusion complexes that are prepared in advance during the manufacturing process. These complexes are incorporated into dosage forms such as tablets, capsules, or injectable solutions, eliminating the need for complex formulation adjustments during administration. The preliminary preparation of stable inclusion complexes simplifies the final formulation and administration while maintaining improved bioavailability
Solution Approach 2:
The patent utilizes derivatives of cyclodextrin with modified chemical parameters (such as hydroxypropyl-β-cyclodextrin or sulfobutyl ether-β-cyclodextrin) that exhibit enhanced solubilizing capabilities and improved stability profiles. By changing the chemical parameters of the cyclodextrin carrier rather than altering the meloxicam molecule itself, the formulation achieves better solubility and stability with minimal increase in complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
Implementation Method 1
cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.